The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis/prognosis/assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

In embodiments the invention relates to means and methods for the treatment of Parkinson's disease. In some embodiments the means and methods involve a GUCY2C agonist. The invention also relates to test systems and cells that are suited to identify new candidate compounds for the treatment of Parkinson's disease.

The present invention provides a mutated histidine decarboxylase suitable for a practical use. Specifically, the present invention provides a mutated histidine decarboxylase having at least one amino acid residue mutated as compared to a wild-type histidine decarboxylase, and having higher histidine decarboxylase activity and/or stability than the wild-type histidine decarboxylase, and also a use thereof. The mutated histidine decarboxylase has Motifs (1) to (6), and an amino acid residue in at least one motif thereof can be mutated. The mutated histidine decarboxylase can also have a mutation of at least one amino acid residue in an amino acid sequence designated by SEQ ID NO: 3 and in a homologous sequence thereto.

A biomarker composition for diagnosing degenerative brain diseases includes main markers and sub-markers as active ingredients by which, in the blood serum of patients with mild cognitive impairment/stage 1 dementia and stage 2 dementia/stage 3 dementia, the levels of main markers amyloid beta 40 (A40), tau, neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP) were measured to be significantly higher than those of a normal control group, the levels of brain-derived nerve growth factor (BDNF) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) were measured to be significantly low, the levels of phospho-tau (AT180) and homocystein (HCY) were measured to be significantly high, and the level of peptidyl-prolyl isomerase (Pin1) was confirmed to be significantly low.

A method for efficiently purifying and detecting 6-hydroxynobilonine in fresh stems of Dendrobium huoshanense uses a gas chromatography-mass spectrometry (GC-MS) method to detect 6-hydroxynobilonine in Dendrobium huoshanense is, i.e., a to-be-detected solution of 6-hydroxynobilonine is extracted from fresh stems of Dendrobium huoshanense, the extraction method is as follows: freeze-drying, smashing and screening fresh stems of Dendrobium huoshanense to obtain dendrobium dry powder, adding water for performing ultrasonic treatment, and then adding a composite enzyme for enzymolysis to obtain an enzymolysis solution; adding acidity alcohol into the enzymolysis solution, extracting for 1 min under an ultra-high pressure, and then taking filtrate; and concentrating the filtrate in vacuum, then purifying using a mixed-mode cation exchanger (MCX) extraction column, eluting with a methanol-acetonitrile solution, collecting eluent, blowing with nitrogen until no water, and then dissolving with methanol and filtering to obtain the to-be-detected solution.

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

The present disclosure pertains to a GUCY2C-binding polypeptide and uses thereof and, specifically, to a GUCY2C-binding polypeptide, a fusion protein including same, a chimeric antigen receptor, an immune cell expressing the chimeric antigen receptor, and a use thereof for treatment and/or diagnosis of cancer.

An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.

The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.